Turning Point Therapeutics Inc logo

Turning Point Therapeutics Inc

$ 76.01 0 (0%) 09:40 AM EST
P/E:
At Loss
P/B:
4.78
Market Cap:
$ 3.81B
Enterprise V:
$ 2.99B
Volume:
2.84M
Avg Vol (2M):
1.19M
Volume:
2.84M
Market Cap $:
3.81B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.19M
Enterprise Value $:
2.99B
PB Ratio:
4.78
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Turning Point Therapeutics Inc
NAICS : 325412 SIC : 2834
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Description
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 165.75
Equity-to-Asset 0.94
Debt-to-Equity 0.01
Debt-to-EBITDA -0.02
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 43.98
Distress
Grey
Safe
Beneish M-Score -18.55
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -40.7
3-Year EPS without NRI Growth Rate -42.5
3-Year FCF Growth Rate -25.7
Name Current Vs Industry Vs History
5-Day RSI 87.5
9-Day RSI 77.27
14-Day RSI 74.83
6-1 Month Momentum % 120.47
12-1 Month Momentum % 11.85

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 16.83
Quick Ratio 16.83
Cash Ratio 16.56

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -34185.81
Net Margin % -33959.03
ROE % -36.23
ROA % -34.59
ROIC % -1414.45
ROC (Joel Greenblatt) % -3648.42
ROCE % -36.39

Financials (Next Earnings Date:2022-11-09 Est.)

TPTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:TPTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.008
EPS (TTM) ($) -6.9
Beta -0.31
Volatility % 133.72
14-Day RSI 74.83
14-Day ATR ($) 0.525604
20-Day SMA ($) 75.111
12-1 Month Momentum % 11.85
52-Week Range ($) 23.77 - 82.2
Shares Outstanding (Mil) 50.07

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Turning Point Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More